Swedish Olink has gone through a formal reorganization, and as of April 1, 2016 it is operating as two separate companies, each with its own distinct focus area.
Olink Proteomics will continue to expand and develop the Proseek Multiplex product line for targeted human protein biomarker discovery.
Olink Bioscience will focus on developing and commercializing the many additional technologies held within Olink’s growing IP portfolio.
The company division reflects both the desire to best serve the needs and expectations of customers in our rapidly growing Proseek business, and the deep seated commitment to develop exciting new molecular tools for the wider scientific community, according to the company.
Advertisement
